Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

FINCKH, Axel et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. In: Arthritis research & therapy, 2014, vol. 16, n° 5, p. 458. doi: 10.1186/s13075-014-0458-4

Article (Published version)

CC BY

Identifiers

PID : unige:45951
DOI : 10.1186/s13075-014-0458-4
PMID : 25315665

Journal ISSN1478-6354

668views

191downloads

Creation01/27/2015 3:26:00 PM

First validation01/27/2015 3:26:00 PM

Update time01/24/2025 2:34:34 PM

Status update01/24/2025 2:34:34 PM

Last indexation01/24/2025 2:42:34 PM

Archive ouverte UNIGE

Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy.

Technical informations